Elbasvir and Grazoprevir
- Generic Name
- Elbasvir and Grazoprevir
- Indication
适用于治疗基因1、4型慢性丙肝的成年患者。
Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole Tablet
Phase 1
Completed
- Conditions
- Deglutition DisordersHepatitis C
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT03817619
- Locations
- 🇳🇱
RTCCS Radboudumc, Nijmegen, Netherlands
ATTIC - Access To Treat in the Community
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 13
- Registration Number
- NCT03797066
- Locations
- 🇬🇧
Kings College Hospital NHS Trust, London, United Kingdom
A Prospective Cohort Study to Improve HCV Care in Dialysis Patients
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Albert Einstein Healthcare Network
- Registration Number
- NCT03791814
Transplanting Hepatitis C Lungs Into Negative Lung Recipients
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 10
- Registration Number
- NCT03724149
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2019-01-09
- Target Recruit Count
- 82
- Registration Number
- NCT03186365
- Locations
- 🇨🇳
Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 20
- Registration Number
- NCT03146741
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)
- First Posted Date
- 2017-05-08
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT03143998
Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant
Phase 4
Withdrawn
- Conditions
- Renal Failure ChronicHepatitis C
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT03093740
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
The Dublin Zepatier Study
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Mater Misericordiae University Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT02895958
- Locations
- 🇮🇪
Thompson Centre, Dublin, Ireland
Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
Phase 4
Completed
- Conditions
- Hepatitis CEnd-Stage Renal Disease
- Interventions
- First Posted Date
- 2016-05-24
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 10
- Registration Number
- NCT02781649
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath